← Eichor
Study identifier: NCT06782880 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Fecal Microbiota Transplantation for the Prevention of Infectious Complications After Liver Transplantation

Condition: Fecal Microbiota Transplantation · Orthotopic Liver Transplantation · Multi-drug Resistant Bacteria  ·  Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

PhaseNA
Planned participants144
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

The increasing emergence and spread of MDRB represents a major public health problem, with higher mortality in patients experiencing infections. Cirrhotic patients listed for OLT and after OLT are at high risk of MDRB colonization or infection due to the large use of broad-spectrum antibiotics in the post-transplant setting. Therefore, effective decolonization strategies in this particular setting are urgently needed. The investigators hypothesize that heterologous FMT can reduce infections rates in the pre-and post- OLT setting by MDRB decolonization and restoration of a more physiological microbiome.

This description comes directly from the study's public registry record.

Talk to the study team

Giovanni Barbara, MD  ·  +390512144103  ·  giovanni.barbara@unibo.it

Always discuss trial participation with your own doctor first.

Locations (1)

IRCCS Azienda Ospedaliero-Universitaria di BolognaBologna, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06782880